natgillin/translations-raw huggingface dataset:
Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC and a 35 min prolongation of time to peak plasma concentration was observed. 
Po uporabi 850 mg odmerka so ugotovili 40 % manjšo največjo koncentracijo v plazmi, 25 % zmanjšanje AUC in 35-minutno podaljšanje časa do največje koncentracije v plazmi.
• redness of the skin (rash) or itching. 
• pordelost kože (izpuščaj) ali srbenje.
• nausea, vomiting 
• siljenje na bruhanje, bruhanje
The pharmacokinetics of saxagliptin and its major metabolite were similar in healthy subjects and in patients with type 2 diabetes. 
Farmakokinetika saksagliptina in njegovega glavnega presnovka sta bili pri zdravih preiskovancih in bolnikih s sladkorno boleznijo tipa 2 podobni.
GENERATION was a 52-week glycaemic control study in 720 elderly patients, the mean age was 72.6 years; 433 subjects (60.1%) were < 75 years of age, and 287 subjects (39.9%) were ≥ 75 years of age. 
Študija GENERATION je bila 52-tedenska študija urejenosti glikemije pri 720 starejših bolnikih, povprečno starih 72,6 let; 433 bolnikov (60,1 %) je bilo starih < 75 let, 281 bolnikov (39,9 %) pa je bilo starih ≥ 75 let.
The clinical significance of this decrease in lymphocyte count relative to placebo is not known. 
Klinični pomen zmanjšanja števila limfocitov, v primerjavi s placebom, ni znan.
Another secondary endpoint, all-cause mortality, occurred at a rate of 5.1% in the saxagliptin group and 4.6% in the placebo group (see Table 7). 
Drug sekundarni opazovani dogodek, umrljivost zaradi vseh vzrokov, se je v skupini s saksagliptinom pojavil v 5,1 % in v skupini s placebom v 4,6 % (glejte preglednico 7).
If you have or have had a disease of the pancreas; 
če imate ali ste kdaj imeli bolezen trebušne slinavke (pankreasa).
For the major metabolite, renal clearance values were comparable to estimated glomerular filtration rate. 
Za glavni presnovek so bile vrednosti ledvičnega očistka primerljive ocenjeni hitrosti glomerularne filtracije.
If this happens you must stop taking Komboglyze and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. 
V tem primeru morate prenehati jemati zdravilo Komboglyze in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
• muscle pain (myalgia) 
• bolečina v mišici (mialgija)
Pack sizes of 14, 28, 56 and 60 film-coated tablets in non-perforated blisters. 
Velikosti pakiranj s 14, 28, 56 in 60 filmsko obloženimi tabletami v neperforiranih pretisnih omotih.
Use with medicinal products known to cause hypoglycaemia Insulin and sulphonylureas are known to cause hypoglycaemia. 
Uporaba z zdravili za katera je znano, da povzročajo hipoglikemijo Znano je, da insulin in sulfonilsečnine povzročajo hipoglikemijo.
Saxagliptin also resulted in a significantly lower proportion of patients with hypoglycaemia, 3% (19 events in 13 subjects) vs. 36.3% (750 events in 156 patients) for glipizide. 
Saksagliptin je bil povezan tudi z značilno manjšim deležem hipoglikemij (3 %; 19 dogodkov pri 13 osebah) kot glipizid (36,3 %; 750 dogodkov pri 156 bolnikih).
Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. 
Metformin je bigvanid z antihiperglikemičnimi učinki, ki zmanjšuje bazalno in postprandialno glukozo v plazmi.
The SAVOR trial included 8240 patients treated with saxagliptin 5 mg or 2.5 mg once daily and 8173 patients on placebo. 
Preskušanje SAVOR je zajelo 8240 bolnikov, zdravljenih z 2,5 mg ali 5 mg saksagliptina enkrat na dan, in 8173 bolnikov, ki so prejemali placebo.
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition provided that renal function has been re-evaluated and found to be stable. 
Zdravljenje se sme ponovno uvesti najmanj 48 ur po kirurškem posegu ali začetku peroralnega prehranjevanja, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno.
What Komboglyze looks like and contents of the pack 
Izgled zdravila Komboglyze in vsebina pakiranja
You should call your doctor if you experience the following side effect: • severe joint pain. 
Posvetujte se z zdravnikom, če se vam pojavijo naslednji neželeni učinki: • hude bolečine v sklepih.
Stop taking Komboglyze and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Takoj prenehajte jemati zdravilo Komboglyzein se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
Do not use this medicine if the package is damaged or shows signs of tampering. 
Ne uporabljajte tega zdravila, če opazite, da je pakiranje poškodovano ali ima vidne znake, da ga je že kdo odpiral.
If you need to have an injection of contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Komboglyze before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Komboglyze.
During postmarketing experience, including spontaneous reports and clinical trials, the following adverse reactions have been reported with the use of saxagliptin: serious hypersensitivity reactions, including anaphylactic reaction, anaphylactic shock, and angioedema. 
Iz izkušenj iz obdobja trženja, vključno s spontanimi poročili in kliničnimi preskušanji, so glede uporabe saksagliptina poročali o naslednjih neželenih učinkih: resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, anafilaktičnim šokom in angioedemu.
However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental toxicity in these litters was limited to foetal body weight decrements of 7%, and a low incidence of delayed ossification of the foetal hyoid. 
Toda med preživelimi samicami z ocenljivimi legli, je bila maternalna toksičnost omejena na mejno zmanjšanje telesne mase od 21. do 29. dne gestacije; spremljajoči razvojni toksični učinki pri teh leglih so bili omejeni na 7 % zmanjšanje telesne mase plodov in majhno incidenco zapoznele osifikacije plodove hioidne kosti.
Komboglyze should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin. 
Zdravilo Komboglyze je treba uporabljati dvakrat na dan in s hrano, da bi zmanjšali z metforminom povezane neželene učinke na prebavilih.
If a serious hypersensitivity reaction to saxagliptin is suspected, discontinue this medicinal product, assess for other potential causes for the event, and institute alternative treatment for diabetes (see sections 4.3 and 4.8). 
Če se pojavi sum na resno preobčutljivostno reakcijo, je potrebno prekiniti zdravljenje s tem zdravilom, preučiti morebitne druge vzroke za dogodek, in uvesti drugo zdravljenje za sladkorno bolezen (glejte poglavji 4.3 in 4.8).
Hypoglycaemia may affect your ability to drive and use machines or work with safe foothold and there is a risk of hypoglycaemia when taking this medicine in combination with medicines known to cause hypoglycaemia such as insulin and sulphonylureas. 
Hipoglikemija lahko poslabša vašo sposobnost za upravljanje vozil in strojev ter za dela z varno oporo; tveganje za hipoglikemijo obstaja, če to zdravilo jemljete v kombinaciji z zdravili, za katera je znano, da povzročajo hipoglikemijo (npr. insulin in sulfonilsečnine).
Primary composite endpoint: MACE Secondary composite endpoint: MACE plus All-cause mortality 
Sekundarni sestavljeni opazovani dogodek: MACE plus Umrljivost zaradi vseh vzrokov
Administration with food (a high-fat meal) resulted in no change in saxagliptin Cmax and a 27% increase in AUC compared with the fasted state. 
Uporaba s hrano (zelo masten obrok) ni spremenila Cmax saksagliptina, njegovo AUC pa je, v primerjavi z uporabo na tešče, povečala za 27 %.
• Komboglyze is available in aluminium foil blister. 
• Zdravilo Komboglyze je na voljo v pretisnem omotu iz aluminijaste folije.
Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs, ATC code: A10BD10. 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov Oznaka ATC: A10BD10
The major metabolite of saxagliptin is also a selective, reversible, competitive DPP4 inhibitor, half as potent as saxagliptin. 
Tudi glavni presnovek saksagliptina je selektiven, reverzibilen, kompetitiven zaviralec DPP4, pol tako močan kot saksagliptin.
In postmarketing experience of saxagliptin, there have been spontaneously reported adverse reactions of acute pancreatitis. 
Iz izkušenj v obdobju trženja saksagliptina so spontano poročali o neželenem učinku akutnem pankreatitisu.
SAVOR trial results 
Rezultati preskušanja SAVOR
This medicineshould not be used to treat this condition; 
Tega zdravila se ne sme uporabljati za zdravljenje te bolezni.
Immune system disorders Hypersensitivity reactions 
Bolezni imunskega sistema preobčutljivostne reakcije
In patients with type 2 diabetes, administration of saxagliptin led to inhibition of DPP4 enzyme activity for a 24-hour period. 
Pri bolnikih s sladkorno boleznijo tipa 2 je uporaba saksagliptina zavrla delovanje encima DPP4 za 24 ur.
The increased risk of overall and major hypoglycaemia was primarily observed in subjects with A1C < 7% at baseline. 
Večje tveganje za vse hipoglikemije in hujše hipoglikemije so ugotovili predvsem med preiskovanci, ki so imeli izhodiščno A1c < 7 %.
Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in the case of fasting, malnutrition or hepatic impairment due to the metformin active substance of Komboglyze (see section 4.4). 
Zastrupitev z alkoholom je povezana s povečanim tveganjem za laktacidozo, zlasti ob postenju, podhranjenosti ali okvari jeter, zaradi vsebnosti učinkovine metformina v zdravilu Komboglyze (glejte poglavje 4.4).
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. NSAID, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
The results of bioequivalence studies in healthy subjects demonstrated that Komboglyze combination tablets are bioequivalent to co-administration of corresponding doses of saxagliptin and metformin hydrochloride as individual tablets. 
Rezultati bioekvivalenčnih študij pri zdravih osebah so pokazali, da je kombinacija učinkovin v tableti Komboglyze bioekvivalentna sočasni uporabi ustreznih odmerkov saksagliptina in metforminijevega klorida v ločenih tabletah.
Side effects seen when taking saxagliptin alone: Common 
Neželeni učinki, ki so jih zabeležili med jemanjem samega saksagliptina: Pogosti
In addition, saxagliptin did not meaningfully alter the pharmacokinetics of metformin, glibenclamide, pioglitazone, digoxin, simvastatin, the active components of a combined oral contraceptive (ethinyl estradiol and norgestimate), diltiazem or ketoconazole. 
Poleg tega saksagliptin ni pomembno spremenil farmakokinetike metformina, glibenklamida, pioglitazona, digoksina, simvastatina, učinkovin v kombiniranih peroralnih kontraceptivih (etinilestradiola in norgestimata), diltiazema ali ketokonazola.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischaemic stroke. 
Primarni opazovani dogodek varnosti (neinferiornosti) in učinkovitosti (superiornosti) je bil sestavljen opazovani dogodek, ki je obsegal čas do prvega pojava katerega od naslednjih hudih neželenih kardiovaskularnih dogodkov: kardiovaskularne smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
Concomitant use not recommended 
Kombinacije, ki niso priporočljive
Table 5 Key efficacy results in placebo-controlled, combination therapy studies of saxagliptin and metformin 
Preglednica 5 Ključni rezultati o učinkovitosti v s placebom kontrolirani študiji kombiniranega zdravljenja s saksagliptinom in metforminom
No data are available with regard to overdose of Komboglyze. 
Podatkov o prevelikem odmerjanju z zdravilom Komboglyze ni.
After an oral glucose load, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations. 
Po peroralni obremenitvi z glukozo je to zavrtje DPP4 povzročilo 2- do 3-kratno povečanje koncentracije aktivnih inkretinskih hormonov v obtoku (vključno z glukagonu podobnim peptidom-1 (GLP-1) in od glukoze odvisnim insulinotropnim polipeptidom (GIP)), zmanjšalo koncentracijo glukagona in povečalo od glukoze odvisno odzivnost celic beta, zaradi česar sta se povečali koncentracija insulina in C-peptida.
Postmarketing experience from clinical trials and spontaneous reports Table 3 shows additional adverse reactions which have been reported in postmarketing experience with saxagliptin. 
Izkušnje iz kliničnih preskušanj in spontana poročila iz obdobja trženja Preglednica 3 prikazuje dodatne neželene učinke o katerih so poročali iz izkušenj v obdobju trženja saksagliptina.
In the confirmatory full analysis set, mean reductions were -0.4% and -0.6% respectively for saxagliptin and sitagliptin, with median reductions of -0.5% for both groups. 
Potrditvena analiza polnega nabora je pokazala za saksagliptin povprečno zmanjšanje za -0,4 % in za sitagliptin za -0,6 %; mediano zmanjšanje je bilo v obeh skupinah -0,5 %.
• in patients already being treated with the combination of saxagliptin and metformin as separate tablets. 
• pri bolnikih, ki že prejemajo kombinacijo saksagliptina in metformina v ločenih tabletah.
Studies in animals have shown excretion of both saxagliptin and/or metabolite and metformin in milk. 
Študije na živalih so pokazale, da se saksagliptin in/ali njegov presnovek in metformin izločajo v mleko.
The effect on HbA1c observed at Week 24 was sustained at Week 52. 
Učinek na HbA1c, opažen po 24 tednih, se je ohranil tudi po 52 tednih.
- In patients with moderate renal impairment that have GFR ≥ 30 to < 45 mL/min, in the absence of other conditions that may increase the risk of lactic acidosis, the dose is 2.5 mg/1000 mg or 2.5 mg/850 mg once daily. 
- Pri bolnikih z zmerno okvaro ledvic, ki imajo GFR od ≥ 30 do <45 ml/min, v odsotnosti drugih stanj, ki bi povečevala tveganje za laktacidozo, je odmerek 2,5 mg/1000 mg ali 2,5 mg/850 mg enkrat na dan. Tem bolnikom ni priporočljivo uvesti zdravila.
Reductions in HbA1c from baseline to Week 24 were observed in all evaluated subgroups defined by baseline HbA1c, with greater reductions observed in patients with a baseline HbA1c ≥ 10% (see Table 5). 
Zmanjšanje HbA1c od izhodišča do 24. tedna so opazili v vseh ocenjenih podskupinah, določenih glede na izhodiščni HbA1c; večja zmanjšanja so ugotovili pri bolnikih, ki so imeli izhodiščni HbA1c ≥ 10 % (glejte preglednico 3).
The decreases in lymphocyte count were not associated with clinically relevant adverse reactions. 
Zmanjšanega števila limfocitov niso spremljali klinično pomembni neželeni učinki.
If you need to have major surgery, you must stop taking Komboglyze during and for some time after the procedure. 
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Komboglyze.
The biotransformation of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). 
Biotransformacija saksagliptina poteka predvsem prek citokroma P450 3A4/5 (CYP3A4/5).
Frequency of adverse reactions by treatment regimen 
Pogostnost neželenih učinkov po shemi zdravljenja
Placebo-corrected mean change in HbA1c (%) (95% CI) 
Na placebo korigirana povprečna sprememba HbA1c (%) (95 % IZ)
• infection of the upper airways 
• okužba zgornjih dihal
What Komboglyze is used for This medicine is used to treat a type of diabetes called ‘type 2 diabetes'. 
To zdravilo uporabljamo za zdravljenje vrste sladkorne bolezni, imenovane "sladkorna bolezen tipa 2".
During post-approval use of saxagliptin, additional side effects have been reported that include serious allergic reactions (anaphylaxis), and swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing. 
V obdobju po prihodu saksagliptina na tržišče so poročali o dodatnih neželenih učinkih, ki vključujejo resne alergijske reakcije (anafilakso), in otekanje obraza, ustnic, jezika in žrela, kar lahko povzroči težave pri dihanju ali požiranju.
For patients inadequately controlled on maximal tolerated dose of metformin monotherapy Patients not adequately controlled on metformin alone should receive a dose of this medicinal product equivalent to the total daily dose of saxagliptin 5 mg, dosed as 2.5 mg twice daily, plus the dose of metformin already being taken. 
Bolniki, ki so nezadostno urejeni z največjim toleriranim odmerkom metformina v monoterapiji Bolniki, ki so nezadostno urejeni z metforminom samim, morajo dobiti odmerek tega zdravila, ki ustreza celotnemu dnevnemu odmerku 5 mg saksagliptina, odmerjanem 2,5 mg dvakrat na dan, ter že dotlej uporabljanemu odmerku metformina.
Similar HbA1c reductions versus placebo were achieved for patients receiving saxagliptin 5 mg add-on to insulin regardless of metformin use (-0.4% for both subgroups). 
Podobna zmanjšanja HbA1c v primerjavi s placebom so bila dosežena pri bolnikih, ki so prejemali 5 mg saksagliptina kot dodatek insulinu, ne glede na uporabo metformina (-0,4 % za obe podskupini).
The study population included those ≥ 65 years (n=8561) and ≥ 75 years (n=2330), with normal or mild renal impairment (n=13916) as well as moderate (n=2240) or severe (n=336) renal impairment. 
Populacija v študiji je zajela bolnike, stare ≥ 65 let (n = 8.561) in ≥ 75 let (n = 2.330), z normalnim delovanjem ledvic ali blago okvaro ledvic (n = 13.916) ter tudi zmerno (n = 2.240) ali hudo (n = 336) okvaro ledvic.
The clinical relevance of the skin lesions is not known, however, clinical correlates to skin lesions in monkeys have not been observed in human clinical trials of saxagliptin. 
Klinični pomen kožnih sprememb ni znan, vendar v kliničnih preskušanjih pri človeku niso opazili klinično primerljivih kožnih sprememb pri opicah.
No metabolites have been identified in humans. 
Pri človeku niso identificirali nobenih presnovkov.
Tablet core Povidone K30 
Jedro tablete povidon K30 magnezijev stearat
If a patient presents with severe joint pain, continuation of drug therapy should be individually assessed. 
Če ima bolnik hude bolečine v sklepih, je treba za vsakega bolnika posebej pretehtati, ali naj še naprej jemlje zdravilo.
Talk to your doctor or pharmacist before taking Komboglyze If you have type1diabetes (your body does not produce any insulin). 
Preden vzamete zdraviloKomboglyze, se posvetujte z zdravnikom ali farmacevtom: če imate sladkorno bolezentipa1 (vaše telo ne proizvaja dovolj insulina).
The Cmax and AUC of saxagliptin and its major metabolite increased proportionally to the saxagliptin dose. 
Cmax in AUC saksagliptina in njegovega glavnega presnovka sta naraščali sorazmerno odmerku saksagliptina.
There have been no therapeutic clinical trials conducted with Komboglyze tablets, however, bioequivalence of Komboglyze with co-administered saxagliptin and metformin has been demonstrated (see section 5.2). 
Terapevtska klinična preskušanja s tabletami zdravila Komboglyze niso bila izvedena, vendar je bila dokazana bioekvivalenca zdravila Komboglyze s sočasno uporabljenim saksagliptinom in metforminom (glejte poglavje 5.2).
Skin lesions were not observed at an increased incidence in clinical trials. 
V kliničnih preskušanjih niso opazili večje incidence kožnih sprememb.
Therefore, a lower dose of insulin or sulphonylurea may be required to reduce the risk of hypoglycaemia when used in combination with Komboglyze. 
Zato je za zmanjšanje tveganja za pojav hipoglikemije morda potreben manjši odmerek insulina ali sulfonilsečnine, kadar se uporablja v kombinaciji z zdravilom Komboglyze.
In the SAVOR trial a small increase in the rate for hospitalisation for heart failure was observed in the saxagliptin treated patients compared to placebo, although a causal relationship has not been established (see section 5.1). 
V preskušanju SAVOR so opažali majhen porast deleža sprejemov v bolnišnico zaradi srčnega popuščanja med bolniki, ki so prejemali saksagliptin, v primerjavi s tistimi, ki so prejemali placebo, toda vzročna povezanost ni bila ugotovljena (glejte poglavje 5.1).
Co-administration of saxagliptin and metformin, to pregnant rats and rabbits during the period of organogenesis, was neither embryolethal nor teratogenic in either species when tested at doses yielding systemic exposures (AUC) up to 100 and 10 times the maximum recommended human doses (RHD; 5 mg saxagliptin and 2000 mg metformin), respectively, in rats; and 249 and 1.1 times the RHDs in rabbits. 
Saksagliptin in metformin, sočasno uporabljena pri brejih podganah in kuncih med obdobjem organogeneze, nista bila niti pri eni niti pri drugi vrsti embrioletalna ali teratogena, če sta bila preskušana v odmerkih, ki so povzročili sistemsko izpostavljenost (AUC) do 100- in 10 krat tolikšno kot največja priporočena odmerka za človeka (RHD; 5 mg za saksagliptin in 2000 mg za metformin) pri podganah in 249 in 1,1-krat tolikšno kot največja RHD pri kuncih.
A total of 22% of the administered radioactivity was recovered in faeces representing the fraction of the saxagliptin dose excreted in bile and/or unabsorbed medicinal product from the gastrointestinal tract. 
Skupno 22 % uporabljene radioaktivnost se je pojavilo v blatu; to predstavlja delež odmerka saksagliptina, izločenega v žolč in/ali neabsorbiranega iz prebavil.
Rash is also noted as an adverse event (AE) for saxagliptin (see section 4.8). 
Izpuščaj je zabeležen tudi kot neželen učinek saksagliptina (glejte poglavje 4.8).
Saxagliptin with metformin 
Saksagliptin z metforminom
The overall incidence of reported hypoglycaemia (recorded in daily patient diaries) was 17.1% in subjects treated with saxagliptin and 14.8% among patients treated with placebo. 
Celotna incidenca zabeleženih hipoglikemij (vpisanih v dnevne dnevnike bolnikov) je bila 17,1 % med prejemniki saksagliptina in 14,8 % med prejemniki placeba.
Komboglyze is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: 
Zdravilo Komboglyze je indicirano pri odraslih s sladkorno boleznijo tipa 2 kot dodatek dieti in telesni dejavnosti za izboljšanje urejenosti glikemije: